HebeCell Corp is a Natick, Massachusetts biotech developing allogeneic, off-the-shelf cell therapies grown from induced pluripotent stem cells (iPSCs). Its core invention is a suspension-bioreactor platform, ProtoNK, that produces natural killer (NK) cells indefinitely and at scale - a manufacturing approach the company says no other lab can match. Founded in 2016, HebeCell aims to make cancer and degenerative-disease therapies cheaper, safer, and available without a matched donor, under the tagline 'Incurable no more.'
Shi-Jiang (John) Lu is a stem cell scientist and the founder, President and CEO of HebeCell Corp, a Natick, Massachusetts biotech building off-the-shelf cancer-killing immune cells from pluripotent stem cells. He spent two decades in regenerative medicine, was a top-ranked inventor in the global stem cell patent landscape, and led research at Advanced Cell Technology before that company was absorbed by Astellas. At HebeCell he pioneered a 3D, feeder-free bioreactor process for growing iPSC-derived natural killer (NK) and CAR-NK cells at industrial scale - aiming to make potent immune therapies as standardized and reproducible as a manufactured product.